tetano
Editor, Senior Moderator
Vaccine. 2011 Jul 7. [Epub ahead of print]
The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.
Okike IO, Yung C, Ladhani S, Oeser C, Bennett A, Doerholt K, Storey S, Donaghy S, Butter N, Hoschler K, Sheasby L, Heath PT, Miller E.
Source
Vaccine Institute, St. George's, University of London, London, United Kingdom.
Abstract
BACKGROUND:
In October 2009, the United Kingdom Department of Health recommended vaccination of high-risk groups, including children with HIV, with a novel, oil-in-water AS03 adjuvanted Influenza A (H1N1) vaccine (Pandemrix?). There were no published data available regarding the immunogenicity of this vaccine in such children.
OBJECTIVES:
This study evaluated the immunogenicity of the adjuvanted Influenza A (H1N1) vaccine in HIV-infected children immunised according to national recommendations and assessed the impact of vaccination on individual CD4 counts and HIV viral loads.
METHODS:
HIV-infected children attending outpatient appointments between 01 November and 31 December 2009 were offered two doses of H1N1 vaccine three weeks apart and a blood test before and 3 weeks after the second dose of vaccine. Serum antibody responses were determined by a haemagglutination inhibition (HAI) assay using standard methods.
RESULTS:
Of the 39 children recruited for vaccination, 31 (median age 11.2, range 3.0-17.9 years) received both doses of vaccine and provided pre- and post-vaccination blood samples. Eight children (26%) had baseline HAI titres ≥1:32. After vaccination, 29 children (94%, 95% CI, 78.6-99.2%) had HAI titres ≥1:32 (seroprotection), of whom 27 (87.1%, 95% CI, 70.1-96.4%) had also had a four-fold rise in titres (seroconversion). In the univariate analysis, post-vaccination geometric mean titres (GMTs) were higher among the 21 children receiving highly active anti-retroviral therapy compared with the 10 treatment-na?ve children (GMT 406 [95% CI 218-757] vs. 128 [49-336]; P=0.035), but this was no longer statistically significant when adjusted for prevaccine GMTs. There was no significant impact of vaccination on CD4+ T cell count or HIV viral load.
CONCLUSION:
The AS03B-adjuvanted pandemic Influenza A (H1N1) vaccine is highly immunogenic and appears to be safe in HIV-infected children.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
21742005
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21742005
The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.
Okike IO, Yung C, Ladhani S, Oeser C, Bennett A, Doerholt K, Storey S, Donaghy S, Butter N, Hoschler K, Sheasby L, Heath PT, Miller E.
Source
Vaccine Institute, St. George's, University of London, London, United Kingdom.
Abstract
BACKGROUND:
In October 2009, the United Kingdom Department of Health recommended vaccination of high-risk groups, including children with HIV, with a novel, oil-in-water AS03 adjuvanted Influenza A (H1N1) vaccine (Pandemrix?). There were no published data available regarding the immunogenicity of this vaccine in such children.
OBJECTIVES:
This study evaluated the immunogenicity of the adjuvanted Influenza A (H1N1) vaccine in HIV-infected children immunised according to national recommendations and assessed the impact of vaccination on individual CD4 counts and HIV viral loads.
METHODS:
HIV-infected children attending outpatient appointments between 01 November and 31 December 2009 were offered two doses of H1N1 vaccine three weeks apart and a blood test before and 3 weeks after the second dose of vaccine. Serum antibody responses were determined by a haemagglutination inhibition (HAI) assay using standard methods.
RESULTS:
Of the 39 children recruited for vaccination, 31 (median age 11.2, range 3.0-17.9 years) received both doses of vaccine and provided pre- and post-vaccination blood samples. Eight children (26%) had baseline HAI titres ≥1:32. After vaccination, 29 children (94%, 95% CI, 78.6-99.2%) had HAI titres ≥1:32 (seroprotection), of whom 27 (87.1%, 95% CI, 70.1-96.4%) had also had a four-fold rise in titres (seroconversion). In the univariate analysis, post-vaccination geometric mean titres (GMTs) were higher among the 21 children receiving highly active anti-retroviral therapy compared with the 10 treatment-na?ve children (GMT 406 [95% CI 218-757] vs. 128 [49-336]; P=0.035), but this was no longer statistically significant when adjusted for prevaccine GMTs. There was no significant impact of vaccination on CD4+ T cell count or HIV viral load.
CONCLUSION:
The AS03B-adjuvanted pandemic Influenza A (H1N1) vaccine is highly immunogenic and appears to be safe in HIV-infected children.
Copyright ? 2011. Published by Elsevier Ltd.
PMID:
21742005
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21742005